# Official Journal C 134I/2022

| | ISSN 1977-091X |
| --- | --- |
| Official Journal
  of the European Union | C 134I |
| | |
| English edition | Information and Notices | Volume 6525 March 2022 |

ISSN 1977-091X

Official Journal

of the European Union

C 134I

English edition

Information and Notices

Volume 6525 March 2022

---

| Contents | page |
| --- | --- |
| | IV   Notices |
| | NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES |
| | European Commission |
| 2022/C 134 I/01 | Summary of European Union decisions on marketing authorisations in respect of medicinal products of 25 March 2022
  (Published pursuant to Article 13 or 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council) | 1 |

Contents

page

IV   Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

2022/C 134 I/01

Summary of European Union decisions on marketing authorisations in respect of medicinal products of 25 March 2022
  (Published pursuant to Article 13 or 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council)

(Published pursuant to Article 13 or 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council

1

---

| EN | |
| --- | --- |

EN

---

IV Notices

NOTICES FROM EUROPEAN UNION INSTITUTIONS, BODIES, OFFICES AND AGENCIES

European Commission

| 25.3.2022 | EN | Official Journal of the European Union | CI 134/1 |
| --- | --- | --- | --- |

25.3.2022

EN

Official Journal of the European Union

CI 134/1

---

Summary of European Union decisions on marketing authorisations in respect of medicinal products of 25 March 2022

(Published pursuant to Article 13 or 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council (1))

(2022/C 134 I/01)

| — | Issuing of a marketing authorisation (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted













  Date of the decision | Name of the medicinal product | INN (International Non-Proprietary Name) | Holder of the marketing authorisation | Number of the entry in the Community Register | Pharmaceutical form | ATC code (Anatomical Therapeutic Chemical Code) | Date of notification |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 25.3.2022 | EVUSHELD | tixagevimab / cilgavimab | AstraZeneca AB
  151 85 Södertälje, Sverige | EU/1/22/1651 | Solution for injection | J06BD03 | 25.3.2022 |

—

Issuing of a marketing authorisation (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted

Date of the decision

Name of the medicinal product

INN (International Non-Proprietary Name)

Holder of the marketing authorisation

Number of the entry in the Community Register

Pharmaceutical form

ATC code (Anatomical Therapeutic Chemical Code)

Date of notification

25.3.2022

EVUSHELD

tixagevimab / cilgavimab

AstraZeneca AB

151 85 Södertälje, Sverige

EU/1/22/1651

Solution for injection

J06BD03

25.3.2022

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

| European Medicines Agency |
| --- |
| Domenico Scarlattilaan 6 |
| 1083 HS Amsterdam |
| NETHERLANDS |

European Medicines Agency

Domenico Scarlattilaan 6

1083 HS Amsterdam

NETHERLANDS

---

(1)  OJ L 136, 30.4.2004, p. 1.

---